Clinical trial
An Investigational Immuno-therapy Trial of Pomalidomide and Low-dose…
NCT02654132 · Bristol-Myers Squibb, Industry · Completed
Key facts
| NCT number | NCT02654132 |
|---|---|
| Title | An Investigational Immuno-therapy Trial of Pomalidomide and Low-dose Dexamethasone With or Without Elotuzumab to Treat Refractory and Relapsed and Refractory Multiple Myeloma (ELOQUENT-3) |
| Official title | An Open Label, Randomized Phase 2 Trial of Pomalidomide/Dexamethasone With or Without Elotuzumab in Relapsed and Refractory Multiple Myeloma (ELOQUENT-3) |
| Lead sponsor | Bristol-Myers Squibb, Industry |
| Collaborators | Celgene Industry AbbVie |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Multiple Myeloma |
| Intervention type | Drug |
| Interventions | Elotuzumab, Pomalidomide, Dexamethasone |
| Enrollment | 117 |
| Start date | Mar 18, 2016 |
| Primary completion | Jan 17, 2018 |
| Completion | Oct 21, 2021 |
| First posted | Jan 13, 2016 |
| Last update posted | Nov 1, 2022 |
| Countries | Australia, Canada, France, Germany, Greece, Italy, Japan, Netherlands, Poland, Spain, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: